Abstract
The new field of neuroethics has recently emerged following unprecedented developments in the neurosciences. Neuroimaging and cognitive enhancement in particular are demanding ethical debate. For example, neuroscientists are able to measure, with increasing accuracy, intimate personal biases and thoughts as they occur in the brain. “Smart drugs” are now available that can effectively and safely enhance mental functioning in both healthy and clinical populations. This article describes the scientific principles behind these technologies, and urges the development of ethical principles based on a clear understanding of them. Europe should take the United States’ lead in devoting resources specifically intended to examine neuroethical concerns within European healthcare and legal frameworks.
Zusammenfassung
Die zahlreichen Entwicklungen in den Neurowissenschaften haben kürzlich zur Entstehung des neuen Feldes der Neuroethik geführt. Vor allem die Möglichkeiten von Neuro-Bildgebung und kognitiver Leistungssteigerung machten eine ethische Debatte erforderlich. So sind Neurowissenschaftler heute in der Lage, mit zunehmender Genauigkeit intime persönliche Neigungen und Gedanken zu messen, sobald sie im Gehirn erscheinen. Zudem gibt es „Smart Drugs”, die mentale Funktionen sowohl in gesunden als auch in klinischen Populationen auf effektive und sichere Weise steigern können. In diesem Beitrag beschreiben wir die wissenschaftlichen Prinzipien hinter diesen Technologien und drängen auf die Entwicklung ethischer Prinzipien auf der Grundlage eines klaren Verständnisses besagter Technologien. Europa sollte dem Beispiel der Vereinigten Staaten folgen und Mittel zur Verfügung stellen, die spezifisch der Untersuchung neuroethischer Belange innerhalb des europäischen Gesundheitswesens und der Gesetzgebung in Europa dienen.
Resume´
Des développements sans précédent dans les sciences neurologiques ont récemment débouché sur l’émergence du nouveau domaine de la neuro-éthique. La neuroimagerie et l’accroissement du rendement cognitif exigent en particulier un débat éthique. Par exemple, les neuroscientifiques sont en mesure aujourd’hui de mesurer avec une précision croissante les inclinaisons et les pensées intimes personnelles dès leur apparition dans le cerveau. Il existe à présent des « smart drugs », des molécules intelligentes, qui permettent de renforcer de manière efficace et sûre les fonctions mentales de populations saines comme cliniques. Le présent article décrit les principes scientifiques qui se cachent derrière ces technologies et considère qu’il est urgent de développer des principes éthiques fondés sur une compréhension claire de ces technologies. L’Europe devrait suivre l’exemple des États-Unis et consacrer des ressources spécialement destinées à étudier les questions de neuro-éthique au sein de la santé publique européenne et de ses cadres législatifs.
Similar content being viewed by others
References
Ambrose PJ (1997) Doping control in sports - a perspective from the 1996 Olympic Games. Am J Health Syst Pharm 54:1053–1057
Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J (2005) Cost of disorders of the brain in Europe. Eur J Neurol 12(Suppl 1):1–27
Aron AR, Dowson JH, Sahakian BJ, Robbins TW (2003) Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 54:1465–1468
Associated Press (2004) Scientists scan brains for political clues. Associated Press via CNN. http://www.olm.blythe-systems.com/pipermail/nytr/Week-of-Mon-20041101/008470.html Accessed 5 January 2005
Babcock Q, Byrne T (2000) Student perceptions of methylphenidate abuse at a public liberal arts college. J Am Coll Health 49:143–145
BBC News (2004) Mentally ill man executed in US. http://www.news.bbc.co.uk/1/hi/world/americas/3374831.stm Accessed 7 January 2004
Beauchamp T, Walters L (2002) Contemporary issues in bioethics. Wadsworth Publishing Company, Belmont, California
Boire RG, Ruiz-Sierra J (2003) Supreme Court upholds right to refuse mind-altering drugs. http://www.cognitiveliberty.org/news/US_v_Sell_decision.htm Accessed 31 August 2004
Brown D (2000) Performance maintenance during continuous flight operations. A guide for flight surgeons NAVMED P-6410. 1st edn. Naval Aerospace Medical Research Laboratory, Penascola, Florida
Butcher J (2003) Cognitive enhancement raises ethical concerns. Academics urge pre-emptive debate on neurotechnologies. Lancet 362:132–133
Canli T, Amin Z (2002) Neuroimaging of emotion and personality: scientific evidence and ethical considerations. Brain Cogn 50:414–431
Caplan A (2002) No-Brainer: can we cope with the ethical ramifications of new knowledge of the human brain? In: Neuroethics: mapping the field conference proceedings, San Francisco, California. The Dana Press, New York, 13–14 May 2002, pp 95–106
Cardenas DD, McLean A Jr, Farrell-Roberts L, Baker L, Brooke M, Haselkorn J (1994) Oral physostigmine and impaired memory in adults with brain injury. Brain Inj 8:579–587
Carlezon WA, Jnr, Konradi C (2004) Understanding the neurobiological consequences of early exposure to psychotropic drugs: linking behavior with molecules. Neuropharmacology 47:47–60
Dale JR, Appelbe GE, Wingfield J (2001) Dale and Appelbe’s Pharmacy Law and Ethics, 7th edn. Pharmaceutical Press, London
Duka T, Sahakian BJ, Turner DC (2005) Experimental psychology and research into brain science, Addiction and Drugs http://www.foresight.gov.uk/Brain_Science_Addiction_and_Drugs/Reports_and_Publications/ScienceReviews/Experimental%20Psychology.pdf Accessed 13 July 2005
Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW (1997) Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology (Berl) 131:196–206
Farah MJ (2002) Emerging ethical issues in neuroscience. Nat Neurosci 5:1123–1129
Farah MJ, Illes J, Cook-Deegan R, Gardner H, Kandel E, King P, Parens E, Sahakian B, Wolpe PR (2004) Neurocognitive enhancement: what can we do and what should we do? Nat Rev Neurosci 5:421–425
Farah MJ, Wolpe PR (2004) Monitoring and manipulating brain function: new neuroscience technologies and their ethical implications. Hastings Cent Rep 34:35–45
Ganis G, Kosslyn SM, Stose S, Thompson WL, Yurgelun-Todd DA (2003) Neural correlates of different types of deception: an fMRI investigation. Cereb Cortex 13:830–836
Garoff RJ, Slotnick SD, Schacter DL (2005) The neural origins of specific and general memory: the role of the fusiform cortex. Neuropsychologia 43:847–859
Geyer MA, Tamminga CA (2004) Measurement and treatment research to improve cognition in schizophrenia: neuropharmacological aspects. Psychopharmacology 174:1–2
Gillon R (1994) Medical ethics: four principles plus attention to scope. BMJ 309:184–188
Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz SC, Weinberger DR (1993) The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 162:43–48
Illes J (2003) Neuroethics in a new era of neuroimaging. Am J Neuroradiol 24:1739–1741
Illes J, Kirschen MP, Gabrieli JD (2003) From neuroimaging to neuroethics. Nat Neurosci 6:205
Illes J, Racine E (2005) Imaging or imagining? A neuroethics challenge informed by genetics. Am J Bioeth 5:5–18
Kiehl KA, Smith AM, Mendrek A, Forster BB, Hare RD, Liddle PF (2004) Temporal lobe abnormalities in semantic processing by criminal psychopaths as revealed by functional magnetic resonance imaging. Psychiatry Res 130:297–312
Kuhse H, Singer P (2001) A companion to bioethics. Blackwell Publishers, Oxford
Langleben DD, Loughead JW, Bilker WB, Ruparel K, Childress AR, Busch SI, Gur RC (2005) Telling truth from lie in individual subjects with fast event-related fMRI. Hum Brain Mapp 26(4):262–272
Langleben DD, Schroeder L, Maldjian JA, Gur RC, McDonald S, Ragland JD, O’Brien CP, Childress AR (2002) Brain activity during simulated deception: an event-related functional magnetic resonance study. Neuroimage 15:727–732
Leshner AI (2005) It’s time to go public with neuroethics. Am J Bioeth 5(2):1–4
Lorberbaum JP, Bohning DE, Shastri A, Nahas Z, George MS (2004) Functional magnetic resonance imaging for the psychiatrist. http://www.musc.edu/psychiatry/fnrd/primer_fmri.htm Accessed 5 October 2004
Mann EM, Ikeda Y, Mueller CW, Takahashi A, Tao KT, Humris E, Li BL, Chin D (1992) Cross-cultural differences in rating hyperactive-disruptive behaviors in children. Am J Psychiatry 149:1539–1542
Marcus D (2002) In: Neuroethics: mapping the field conference proceedings, San Francisco, California. The Dana Press, New York, 13–14 May 2002
McCabe SE, Knight JR, Teter CJ, Wechsler H (2005) Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 100:96–106
McClure SM, Li J, Tomlin D, Cypert KS, Montague LM, Montague PR (2004) Neural correlates of behavioral preference for culturally familiar drinks. Neuron 44:379–87
McDowell S, Whyte J, D’Esposito M (1998) Differential effect of a dopaminergic agonist on prefrontal function in traumatic brain injury patients. Brain 121:1155–1164
Mehta MA, Calloway P, Sahakian BJ (2000) Amelioration of specific working memory deficits by methylphenidate in a case of adult attention deficit/hyperactivity disorder. J Psychopharmacol 14:299–302
Mitchell RL, Elliott R, Woodruff PW (2001) fMRI and cognitive dysfunction in schizophrenia. Trends Cogn Sci 5:71–81
Moll J, de Oliveira-Souza R, Moll FT, Ignacio FA, Bramati IE, Caparelli-Daquer EM, Eslinger PJ (2005) The moral affiliations of disgust: a functional MRI study. Cogn Behav Neurol 18:68–78
National Audit Office (2003) Safety, quality and efficacy: regulating medicines in the UK. In: Report by the Comptroller and Auditor General HC 255. The Stationery Office, London
Parens E (2002) How far will the term enhancement get us as we grapple with new ways to shape ourselves? In: Neuroethics: mapping the field conference proceedings, San Francisco, California. The Dana Press, New York, 13–14 May 2002, pp 152–158
Phelps EA, O’Connor KJ, Cunningham WA, Funayama ES, Gatenby JC, Gore JC, Banaji MR (2000) Performance on indirect measures of race evaluation predicts amygdala activation. J Cogn Neurosci 12:729–738
Racine E, Bar-Ilan O, Illes J (2005) fMRI in the public eye. Nat Rev Neurosci 6:159–164
Rahman S, Robbins TW, Hodges JR, Mehta MA, Nestor PJ, Clark L, Sahakian BJ (2005) Methylphenidate (‘Ritalin’) can ameliorate abnormal risk-taking behaviour in the frontal variant of frontotemporal dementia. Neuropsychopharmacology. Advanced online publication, 7 September 2005, doi:10.1038/sj.npp.1300886
Rappley MD, Gardiner JC, Jetton JR, Houang RT (1995) The use of methylphenidate in Michigan. Arch Pediatr Adolesc Med 149:675–679
Robbins TW, McAlonan G, Muir JL, Everitt BJ (1997) Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer’s disease. Behav Brain Res 83:15–23
Singer T, Seymour B, O’Doherty J, Kaube H, Dolan RJ, Frith CD (2004) Empathy for pain involves the affective but not sensory components of pain. Science 303:1157–1162
Sonuga-Barke EJS, Minocha K, Taylor EA, Sandberg S (1993) Inter-ethnic bias in teachers ratings of childhood hyperactivity. Br J Dev Psychol 11:187–200
Stark CE, Squire LR (2001) When zero is not zero: the problem of ambiguous baseline conditions in fMRI. Proc Natl Acad Sci USA 98:12760–12766
Timimi S, Moncrieff J, Jureidini J, Leo J, Cohen D, Whitfield C, Double D, Bindman J, Andrews H, Asen E, Bracken P, Duncan B, Dunlap M, Albert G, Green M, Greening T, Hill J, Huws R, Karon B, Kean B, McCubbin M, Miatra B, Mosher L, Parry S, DuBose Ravenel S, Riccio D, Shulman R, Stolzer J, Thomas P, Vimpani G, Wadsworth A, Walker D, Wetzel N, White R (2004) A critique of the international consensus statement on ADHD (discussion 65–69). Clin Child Fam Psychol Rev 7:59–63
Turner DC, Blackwell AD, Dowson JH, McLean A, Sahakian BJ (2005) Neurocognitive effects of methylphenidate in adult attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 178:286–295
Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ (2004a) Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry 55:1031–1040
Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ (2004b) Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29:1363–1373
Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ (2003) Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 165:260–269
Turner DC, Sahakian BJ (2005) The neuroethics of cognitive enhancement. BioSocieties (in press)
Wesensten NJ, Belenky G, Kautz MA, Thorne DR, Reichardt RM, Balkin TJ (2002) Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine. Psychopharmacology (Berl) 159:238–247
Wolpe PR, Foster KR, Langleben DD (2005) Emerging neurotechnologies for lie-detection: promises and perils. Am J Bioeth 5:39–49
Acknowledgements
The Research reported by DCT and BJS was funded by the Wellcome Trust and carried out within the MRC Wellcome Trust Behavioural and Clinical Neuroscience Institute in Cambridge. BJS holds the FC Donders Chair in Psychopharmacology at Utrecht University.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Turner, D.C., Sahakian, B.J. Ethical questions in functional neuroimaging and cognitive enhancement. Poiesis Prax 4, 81–94 (2006). https://doi.org/10.1007/s10202-005-0020-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10202-005-0020-1